Plain Language Summaries

Standalone, citable summaries published in the Future Science Group journals written to be understood by a lay audience

Joanne Walker

Plain language summary of the VOLTAIRE-RA study in patients with moderate-to-severe rheumatoid arthritis

The latest plain language summary of publication from Immunotherapy presents results from the VOLTAIRE-RA study looking at how effective and safe the biosimilar drug BI 695501 is in treating people with rheumatoid arthritis.

Read the summary here.

The original article on which this summary is based is called ‘Similar efficacy, safety and immunogenicity of adalimumab biosimilar BI 695501 and Humira reference product in patients with moderately to severely active rheumatoid arthritis: results from the phase III randomised VOLTAIRE-RA equivalence study’ and was originally published in the journal Annals of the Rhematic Diseases. The original article can be read here.

A plain language summary of the Janssen COVID-19 vaccine effectiveness and safety as a single dose and with a booster

This plain language summary from Future Virology presents the results of two global clinical studies of the Janssen Ad26.COV2.S vaccine against COVID-19. ENSEMBLE study looked at the effectiveness of a single injection of the vaccine. ENSEMBLE2 study looked at the effectiveness of a booster dose of the vaccine given 2 months after the first dose. 

Read the summary here.

The original articles on which this summary is based are:

‘Final analysis of efficacy and safety of single-dose Ad26.COV2.S’ published in the New England Journal of Medicine in 2022. This article is available for free here.

‘Efficacy, safety, and immunogenicity of a booster regimen of Ad26.COV2.S vaccine against COVID-19 (ENSEMBLE2): results of a randomised, double-blind, placebo-controlled, phase 3 trial’ published in The Lancet Infectious Diseases in 2022. This article is available for free here.

Plain language summary of a study looking at heart muscle thickness and kidney function in women with Fabry disease who received agalsidase beta treatment

The new plain language summary of publication in Future Cardiology uses information from the Fabry Registry to understand the effects of agalsidase beta treatment in women with Fabry disease.

Read the full article here.

The original article on which this summary is based is called ‘Cardiomyopathy and kidney function in agalsidase beta-treated female Fabry patients: a pre-treatment vs. post-treatment analysis’ and was originally published in the journal ESC Heart Failure. The original article can be read here.

Osilodrostat for the treatment of Cushing’s disease: a plain language summary of the LINC 4 study

A new plain language summary of publication from Future Rare Diseases discusses the results of the LINC 4 study, which looked at how effective osilodrostat was in patients with Cushing’s disease and what the side effects were.

Read the summary here.

The original article on which this summary is based is called ‘Randomized Trial of Osilodrostat for the Treatment of Cushing Disease’ and was originally published in The Journal of Clinical Endocrinology & Metabolism. The original article can be read here.

Disease stability over five years in people with multiple sclerosis treated with cladribine tablets: a plain language summary

In this plain language summary of publication from Neurodegenerative Disease Management, Dr Gavin Giovannoni and co-authors provide an overview of their article originally published in the journal Advances in Therapy. In this article, the researchers look at the results from the CLARITY and CLARITY Extension studies to determine what effect a 2-year course of treatment with cladribine tablets had on disability over 5 years in people with multiple sclerosis.

Read the full article here.

The original article on which this summary is based is called ‘Long-Term Disease Stability Assessed by the Expanded Disability Status Scale in Patients Treated with Cladribine Tablets 3.5 mg/kg for Relapsing Multiple Sclerosis: An Exploratory Post Hoc Analysis of the CLARITY and CLARITY Extension Studies’ and was originally published in the journal Advances in Therapy. The original article can be read here.